Impact of the 12-gene recurrence score assay on deciding adjuvant chemotherapy for stage II and IIIA/B colon cancer: the SUNRISE-DI study

[1]  R. Labianca,et al.  Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical Trial. , 2020, JAMA oncology.

[2]  E. Oki,et al.  Efficacy and Long-term Peripheral Sensory Neuropathy of 3 vs 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Colon Cancer , 2019, JAMA oncology.

[3]  V. Georgoulias,et al.  Three versus six months adjuvant FOLFOX or CAPOX for high risk stage II and stage III colon cancer patients: the efficacy results of Hellenic Oncology Research Group (HORG) participation to the International Duration Evaluation of Adjuvant chemotherapy (IDEA) project. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  J. Meyerhardt,et al.  Duration of Oxaliplatin-Containing Adjuvant Therapy for Stage III Colon Cancer: ASCO Clinical Practice Guideline. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  R. Labianca,et al.  The hard road to data interpretation: 3 or 6 months of adjuvant chemotherapy for patients with stage III colon cancer? , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  R. Labianca,et al.  Duration of Adjuvant Chemotherapy for Stage III Colon Cancer , 2018, The New England journal of medicine.

[7]  Joseph Kannarkatt,et al.  Adjuvant Chemotherapy for Stage II Colon Cancer: A Clinical Dilemma. , 2017, Journal of oncology practice.

[8]  S. Alberts,et al.  Prospective Evaluation of a 12‐Gene Assay on Patient Treatment Decisions and Physician Confidence in Mismatch Repair Proficient Stage IIA Colon Cancer , 2017, Clinical colorectal cancer.

[9]  E. Oki,et al.  12-Gene Recurrence Score Assay Stratifies the Recurrence Risk in Stage II/III Colon Cancer With Surgery Alone: The SUNRISE Study. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  M. Mishaeli,et al.  Impact of the 12-Gene Colon Cancer Assay on Clinical Decision Making for Adjuvant Therapy in Stage II Colon Cancer Patients. , 2016, Value in Health.

[11]  F. D. De Braud,et al.  Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  S. Dakhil,et al.  Prospective multicenter study of the impact of oncotype DX colon cancer assay results on treatment recommendations in stage II colon cancer patients. , 2014, The oncologist.

[13]  M. Broder,et al.  Effect of the 12-gene colon cancer assay results on adjuvant treatment recommendations in patients with stage II colon cancer , 2014, Current medical research and opinion.

[14]  Margarita Lopatin,et al.  Validation of the 12-gene colon cancer recurrence score in NSABP C-07 as a predictor of recurrence in patients with stage II and III colon cancer treated with fluorouracil and leucovorin (FU/LV) and FU/LV plus oxaliplatin. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  R. Labianca,et al.  Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  R. Schilsky,et al.  Biologic determinants of tumor recurrence in stage II colon cancer: validation study of the 12-gene recurrence score in cancer and leukemia group B (CALGB) 9581. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  D. Kerr,et al.  Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  F. D. De Braud,et al.  Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  S. Paik,et al.  Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  T. Hickish,et al.  Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  R. Labianca,et al.  Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  Quasar Collaborative Group.  Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study , 2007, The Lancet.

[23]  N. Petrelli,et al.  Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  P. Catalano,et al.  Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  T. Hickish,et al.  Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. , 2004, The New England journal of medicine.

[26]  S. Cha,et al.  Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  L. Sobin,et al.  TNM Classification of Malignant Tumours , 1987, UICC International Union Against Cancer.